Your session is about to expire
← Back to Search
FT-2102 +/− Azacitidine/Cytarabine for Acute Myeloid Leukemia
Study Summary
This trial is testing the safety and effectiveness of a new drug, FT-2102 (olutasidenib), as a single agent or in combination with azacitidine or cytarabine, for treating patients with various states of AML/MDS.
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You have cancer that has spread to your brain or other parts of your body and requires immediate treatment or symptom relief.
- Group 1: PH2 Cohort 1 FT-2102 (olutasidenib) Single Agent
- Group 2: PH1 Dose Escalation & Expansion FT-2102 (olutasidenib)
- Group 3: PH1 Esc. and Exp. FT-2102 (olutasidenib)+Cytarabine
- Group 4: PH2 Cohort 2 FT-2102 (olutasidenib) Single Agent
- Group 5: PH2 Cohort 3 FT-2102 (olutasidenib) Single Agent
- Group 6: PH2 Cohort 4 FT-2102 (olutasidenib)+Azacitidine
- Group 7: PH2 Cohort 5 FT-2102 (olutasidenib)+Azacitidine
- Group 8: PH2 Cohort 6 FT-2102 (olutasidenib)+Azacitidine
- Group 9: PH2 Cohort 7 FT-2102 (olutasidenib) Single Agent
- Group 10: PH2 Cohort 8 FT-2102 (olutasidenib)+Azacitidine
- Group 11: PH1 Esc. and Exp. FT-2102 (olutasidenib)+Azacitidine
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are people currently being signed up to participate in this clinical trial?
"According to the listing on clinicaltrials.gov, this study is not currently looking for new participants. The trial was originally posted on 4/1/2016 and the most recent update was on 3/2/2022. There are 2118 other trials that have open recruitment at this time."
Is this particular clinical trial taking place at more than one hospital in America?
"There are 19 active clinical trial sites for this study, located in Nashville, New york, Portland, and other cities."
Are there any limitations as to how many people can join this trial?
"Unfortunately, this study is no longer looking for participants. However, there are presently 1714 trials actively looking for patients with leukemia and myeloid and 404 studies for FT-2102 (olutasidenib) that may be of interest."
What are the precedent studies for FT-2102 (olutasidenib)?
"There are currently 404 ongoing trials researching the efficacy of FT-2102 (olutasidenib), with 87 of them being in Phase 3. New york, New York has a significant presence for these studies, however there are 14257 locations across the world conducting research on FT-2102 (olutasidenib)."
Which condition does FT-2102 (olutasidenib) target?
"FT-2102 (olutasidenib) is the standard of care for meningeal leukemia. Additionally, FT-2102 has shown efficacy in treating other blood disorders like refractory anemias and blast phase chronic myelocytic leukemia."
Share this study with friends
Copy Link
Messenger